120 related articles for article (PubMed ID: 23015453)
1. Substitution with doxorubicin for daunorubicin during induction for high risk pediatric acute lymphoblastic leukemia results in increased toxicity.
Gardner RA; Thomson B; Hawkins DS
Pediatr Blood Cancer; 2013 Feb; 60(2):338-9. PubMed ID: 23015453
[No Abstract] [Full Text] [Related]
2. Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03.
Escherich G; Zimmermann M; Janka-Schaub G;
Pediatr Blood Cancer; 2013 Feb; 60(2):254-7. PubMed ID: 22948968
[TBL] [Abstract][Full Text] [Related]
3. Randomized study comparing 4'-epi-doxorubicin (epirubicin) versus doxorubicin as a part of induction treatment in adult acute lymphoblastic leukemia.
Bhutani M; Kumar L; Vora A; Bhardwaj N; Pathak AK; Singh R; Kochupillai V
Am J Hematol; 2002 Dec; 71(4):241-7. PubMed ID: 12447951
[TBL] [Abstract][Full Text] [Related]
4. A single-center experience of the nationwide daunorubicin shortage: substitution with doxorubicin in adult acute lymphoblastic leukemia.
Patel S; Liedtke M; Ngo D; Medeiros BC
Leuk Lymphoma; 2013 Oct; 54(10):2231-5. PubMed ID: 23383599
[TBL] [Abstract][Full Text] [Related]
5. Treatment of high-risk acute lymphoblastic leukemia with protocols PETHEMA LAL 7/78 and LAL 17/84.
Ortega JJ; Javier G; Olivé T
An Esp Pediatr; 1988 Oct; 29 Suppl 34():72-83. PubMed ID: 3214043
[No Abstract] [Full Text] [Related]
6. [Acute lymphoblastic leukemia in childhood. A 10-year experience with the DFCI 81-01 protocol].
de Lacerda AF; Chagas M; Neto A; Vieira E; Ribeiro MJ; Pereira F; Ambrósio A; Sousinha M
Acta Med Port; 1999; 12(7-11):287-92. PubMed ID: 10707467
[TBL] [Abstract][Full Text] [Related]
7. In vitro cytotoxicity of mitoxantrone, daunorubicin and doxorubicin in untreated childhood acute leukemia.
Kaspers GL; Veerman AJ; Pieters R; van Zantwijk I; Klumper E; Hählen K; de Waal FC; van Wering ER
Leukemia; 1994 Jan; 8(1):24-9. PubMed ID: 8289494
[TBL] [Abstract][Full Text] [Related]
8. The impact of hyperglycemia on risk of infection and early death during induction therapy for acute lymphoblastic leukemia (ALL).
Dare JM; Moppett JP; Shield JP; Hunt LP; Stevens MC
Pediatr Blood Cancer; 2013 Dec; 60(12):E157-9. PubMed ID: 23868820
[TBL] [Abstract][Full Text] [Related]
9. A paediatric case of Candida pericarditis and eosophagus stricture during treatment for acute lymphatic leukaemia.
Dahl C; Fuursted K; Schrøder H
Acta Oncol; 2007; 46(6):859-61. PubMed ID: 17653912
[No Abstract] [Full Text] [Related]
10. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
Weiser MA; Cabanillas ME; Konopleva M; Thomas DA; Pierce SA; Escalante CP; Kantarjian HM; O'Brien SM
Cancer; 2004 Mar; 100(6):1179-85. PubMed ID: 15022284
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with a prolonged hospital stay during induction chemotherapy in newly diagnosed high risk pediatric acute lymphoblastic leukemia.
Warrick K; Althouse SK; Rahrig A; Rupenthal J; Batra S
Leuk Res; 2018 Aug; 71():36-42. PubMed ID: 30005182
[TBL] [Abstract][Full Text] [Related]
12. [Importance of anthracyclines in infants in the treatment of acute lymphoblastic and non-lymphoblastic leukemias].
Leverger G; Bancillon A; Schaison G
Pathol Biol (Paris); 1987 Jan; 35(1):87-90. PubMed ID: 3550617
[TBL] [Abstract][Full Text] [Related]
13. [High-risk acute lymphoblastic leukemia].
Martínez Rubio A; Doñoro Mazario M; Sánchez Luna M; Muro Brussi M; Lamamie de Cleirac P; García-Monge Santidrián S
An Esp Pediatr; 1988 Oct; 29 Suppl 34():66-8. PubMed ID: 3214041
[No Abstract] [Full Text] [Related]
14. Drug may protect children's hearts from chemotherapy.
McBride D
ONS Connect; 2010 Dec; 25(12):15. PubMed ID: 21214085
[No Abstract] [Full Text] [Related]
15. Treatment of acute lymphoblastic leukemia French protocol Fralle 83-87.
Schaison G; Sommelet D; Bancillon A; Perel Y; Leblanc T; Bergeron C; Lejars O; Baruchel A; Lepage E; Leverger G
Leukemia; 1992; 6 Suppl 2():148-52. PubMed ID: 1578919
[No Abstract] [Full Text] [Related]
16. Protective role of black seed oil in doxorubicin-induced cardiac toxicity in children with acute lymphoblastic leukemia.
Hagag AA; Badraia IM; El-Shehaby WA; Mabrouk MM
J Oncol Pharm Pract; 2020 Sep; 26(6):1397-1406. PubMed ID: 31964219
[TBL] [Abstract][Full Text] [Related]
17. Effect of doxorubicin and daunorubicin on the activity of acetylcholinesterase in acute lymphoblastic leukamia.
Niazi IU; Tariq SA; Ali A
J Ayub Med Coll Abbottabad; 2011; 23(2):45-7. PubMed ID: 24800340
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96.
Ribera JM; Oriol A; Sanz MA; Tormo M; Fernández-Abellán P; del Potro E; Abella E; Bueno J; Parody R; Bastida P; Grande C; Heras I; Bethencourt C; Feliu E; Ortega JJ
J Clin Oncol; 2008 Apr; 26(11):1843-9. PubMed ID: 18398150
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for infection-related outcomes during induction therapy for childhood acute lymphoblastic leukemia.
Afzal S; Ethier MC; Dupuis LL; Tang L; Punnett AS; Richardson SE; Allen U; Abla O; Sung L
Pediatr Infect Dis J; 2009 Dec; 28(12):1064-8. PubMed ID: 19773675
[TBL] [Abstract][Full Text] [Related]
20. Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study.
Mandhaniya S; Swaroop C; Thulkar S; Vishnubhatla S; Kabra SK; Xess I; Bakhshi S
J Pediatr Hematol Oncol; 2011 Dec; 33(8):e333-41. PubMed ID: 22042283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
